Science Firsthand: Translating the Promise of Cell Therapy with Bristol Myers Squibb


The story of how chimeric antigen receptor (CAR) T cell therapy went from hypothesis to groundbreaking treatment embodies the challenges, perseverance and ingenuity often synonymous with breakthroughs. “When I look back 10 years ago, I remember the first time somebody described what a CAR T cell was to me, and I was like, wow, that’s really cool, but it doesn’t sound very feasible,” says Bristol Myers Squibb’s Teri Foy, PhD, senior vice president, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle Site lead. Fast forward to today — CAR T cell therapy is one of the most exciting medical innovations of the past two decades.

Committed to improving cell therapy science, Bristol Myers Squibb is advancing a robust pipeline of cell therapy projects. Researchers are finding new targets based on causal human biology, uncovering new ways to engineer the cells and thinking creatively about how to selectively target solid tumors and expand to other disease areas like immune-mediated diseases and neuroscience.